This week in drug discovery (26-30 September)
News round-up by DDW Editor Reece Armstrong.
An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of identifying cancer cells and a manufacturing system could advance the development and production of cell and gene therapies.
AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.
Beckman Coulter Life Sciences has released a call for registrations for its SPRI Grants for Genomic Research, which the company describes as part of its commitment to the next generation of researchers and scientists.
A new method of separating cancer cells from non-cancer cells has been developed by researchers at the Wellcome Sanger Institute, in a boost for those working to better understand cancer biology using single-cell mRNA sequencing.
US biotechnology start-up LivFul has secured a $1.5m investment to expand its work saving lives from malaria and other insect-borne diseases, and to support the company’s growth plans.
PerkinElmer has launched the Cellaca PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity.